11.26  2.66 (30.93%)		04-24 16:00
Open: 10.745 High: 11.575 Volume: 30,139,866		Pre. Close: 8.6 Low: 9.95 Market Cap: 2,931(M)

Short term
Mid term
Targets	6-month :	13.51	1-year :	15.79
Resists	First :	11.57	Second :	13.51
Pivot price	8.42
Supports	First :	7.93	Second :	5.69
MAs	MA(5) :	9.42	MA(20) :	7.82
	MA(100) :	7.53	MA(250) :	8.57
MACD	MACD :	0.8	Signal :	0.5
%K %D	K(14,3) :	82.2	D(3) :	79.9
RSI	RSI(14): 73.7
52-week	High :	13.11	Low :	5.69

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ OGN ] has closed below upper band by 2.1%. Bollinger Bands are 210.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	11.59 - 11.67	11.67 - 11.73
Low:	9.82 - 9.89	9.89 - 9.95
Close:	11.15 - 11.28	11.28 - 11.38

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Mon, 27 Apr 2026
Sun Pharma to acquire Organon for $11.75bn - Pharmaceutical Technology

Mon, 27 Apr 2026
Sun sets out $11.75bn takeover play for Organon - pharmaphorum

Mon, 27 Apr 2026
Sun Pharma puts seal on $11.75B Organon buyout - FirstWord Pharma

Mon, 27 Apr 2026
India’s Sun Pharma to buy US-listed Organon in about $11.8 billion deal - whbl.com

Mon, 27 Apr 2026
Organon To Be Acquired By Sun Pharma In $11.75B Deal, OGN Stock Spikes Nearly 17% On Robinhood 24-Hour Ma - Benzinga

Mon, 27 Apr 2026
Sun Pharma to acquire US-based Organon in $11.75 billion deal, among biggest overseas buys by Indian firm - The Times of India

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	260 (M)
Shares Float	259 (M)
Held by Insiders	0.3 (%)
Held by Institutions	77.5 (%)
Shares Short	22,130 (K)
Shares Short P.Month	16,280 (K)

EPS	0.72
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.89
Profit Margin	3 %
Operating Margin	16.1 %
Return on Assets (ttm)	6.2 %
Return on Equity (ttm)	30.5 %
Qtrly Rev. Growth	-5.4 %
Gross Profit (p.s.)	12.98
Sales Per Share	23.89
EBITDA (p.s.)	6.33
Qtrly Earnings Growth	0 %
Operating Cash Flow	700 (M)
Levered Free Cash Flow	190 (M)

PE Ratio	15.63
PEG Ratio	0
Price to Book value	3.89
Price to Sales	0.47
Price to Cash Flow	4.18

Dividend	0.01
Forward Dividend	0
Dividend Yield	0.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.